|
Home
CME Live Seminars
About the Program
Quick Order
Hotel Registration
Auto Rental
Accreditation
Cancellation Policy
Testimonials
CME Video DVD
CME Audio CD/MP3
Subscribe
Request Brochure
Hold Seat
Testing Online
Faculty
Resources
Contact Us
|
|
|
|
Live CME Seminars
Infectious Diseases CME |
|
|
by Donald Kaye, M.D., M.A.C.P. - Drexel University, College of Medicine; Professor of Medicine; Philadelphia, PA; Elaine T. Kaye, M.D. - Harvard Medical School; Assistant Professor, Division of Dermatology; Attending Physician, Children's Hospital, Boston, MA; Keith S. Kaye, M.D., M.P.H - Wayne State University School of Medicine; Professor of Medicine, Division of Infectious Diseases; Corporate Medical Director of Hospital Epidemiology and Antimicrobial Stewardship, Detroit Medical Center, Detroit, MI; Kenneth Kaye, M.D., F.A.C.P. - Harvard Medical School; Associate Professor of Medicine; Attending Physician, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA and Jerry Zuckerman, M.D. - Jefferson Medical College, Thomas Jefferson University; Assistant Professor of Medicine; Medical Director, Infection Prevention and Control, Division of Infectious Diseases, Albert Einstein Medical Center, Philadelphia, PA.
Learning Objectives
What do our past participants have to say?
Refer a Colleague to Our Website
|
|
Infectious Diseases in the Adult Patient: A Primary Care Update
December 27-31, 2010
Location: Hyatt Regency Sarasota, Florida
| SPECIFIC OBJECTIVES
| | Day 1 | Meningitis and Meningoencephalitis - Upon completion of this session, the participant should be able to use the evidence-based guidelines of the IDSA and the CDC to:
| 1. | Evaluate the epidemiology of meningitis and the different types of meningitis.
| | 2. | Interpret clinical signs and symptoms of different types of meningitis.
| | 3. | Apply the indications for lumbar puncture (LP) and interpret LP results.
| | 4. | Evaluate treatment options and the need for hospitalization and public health notification.
| | New or Emerging Infectious Diseases, Parts 1 & 2: Influenza; C-difficile Infection (CDI). - Upon completion of this session, according to SHEA and HICPAC position papers, and the CDC and WHO recommendations, the participant should be able to:
| | 1. | Evaluate the etiology and pathogenesis of these infections.
| | 2. | Diagnose these infections.
| | 3. | Treat or otherwise manage these infections.
| | 4. | Apply prophylactic measures for these infections.
| | Methicillin Resistant Staphylococcus aureus (MRSA) - Using the evidence-based guidelines from the CDC, IDSA and SHEA, upon completion of this session, the participant should be able to:
| | 1. | Evaluate the epidemiology of MRSA.
| | 2. | Diagnose the important infections caused by MRSA.
| | 3. | Analyze the risk factors and outcomes associated with MRSA control.
| | 4. | Appropriately treat MRSA infections.
|
| | Day 2 | Newer Antibacterial Agents - Upon completion of this session, using FDA publications and approvals as well as IDSA and SHEA evidence-based guidelines, the participant should be able to:
| 1. | Relate the antibacterial spectrum of activity and indications for use.
| | 2. | Employ knowledge of the pharmacology of the agents.
| | 3. | Appropriately prescribe the agents.
| | 4. | Assess side effects, adverse reactions and drug interactions.
| | Urinary Tract Infection - Upon completion of this session, using evidence- based guidelines of the IDSA, AUA and EBM publications, the participant should be able to:
| | 1. | Relate the epidemiology of UTIs.
| | 2. | Illustrate the attributes of lower tract and upper tract infections and reinfections and relapses.
| | 3. | Diagnose chronic bacterial prostatitis.
| | 4. | Use antimicrobial therapy, to include short course therapy.
| | 5. | Select approaches to prevention.
| | Update on Antimicrobial Resistance - Upon completion of this session, using IDSA and SHEA evidence-based guidelines and CDC and WHO surveys, the participant should be able to:
| | 1. | Interpret the pattern of emergence of resistance of certain infecting bacteria.
| | 2. | Analyze the epidemiology that may indicate potential resistance among the organisms discussed, such as:
| a. | Pneumococci;
| | b. | Enterococci;
| | c. | Gram negative bacilli.
|
| | 3. | Use current therapeutic regimens while considering resistance.
| | Herpesvirus Infections - Upon completion of this session, using the recommendations and evidence-based guidelines of ACIP and AAP, the participant should be able to:
| | 1. | Relate the clinically pertinent aspects of herpesvirus infections.
| | 2. | Diagnose the syndromes, clinical complications and attributes of recurrent disease.
| | 3. | Use anti-virals where appropriate in management of herpes virus infections. Viruses to be covered include:
| a. | Herpes simplex virus;
| | b. | Epstein-Barr virus;
| | c. | Cytomegalovirus;
| | d. | Varicella-zoster virus;
| | e. | HHV6.
|
|
| | Day 3 | Hepatitis - Upon completion of this session, using evidence- based guidelines and consensus statements from NIH, CDC, AGA, ACIP, AAP and Association for the Study of Liver Disease, the participant should be able to:
| 1. | Interpret the pathogenesis and clinical manifestations of hepatitis A, B, C, D or E.
| | 2. | Relate differences in complications.
| | 3. | Summarize treatment options for hepatitis B and C.
| | Tuberculosis - Using evidence-based guidelines and recommendations from ATS, IDSA, CDC, and WHO, upon completion of this session, the participant should be able to:
| | 1. | Assess the groups at risk for developing active tuberculosis.
| | 2. | Relate the principles of antituberculous therapy.
| | 3. | Interpret results of tuberculin skin testing.
| | 4. | Treat latent TB infection.
| | Helicobacter pylori Infection - Upon completion of this session, using position statements from AGA, and evidence based guidelines from ACOG, the participant should be able to:
| | 1. | Interpret the clinical manifestations of H. pylori infection.
| | 2. | Use the methods for testing for H. pylori infection.
| | 3. | Treat H. pylori infection.
| | Cellulitis, Necrotizing Fasciitis and the Diabetic Foot Ulcers - Upon completion of this session, using the evidence- based guidelines from the IDSA, the participant should be able to:
| | 1. | Diagnose typical and atypical manifestations.
| | 2. | Evaluate the pathogenesis.
| | 3. | Apply the principles of medical and surgical treatment.
| | 4. | Assess the prognosis.
|
| | Day 4 | Adult Immunizations, Part I - Upon completion of this session, the participant should be able to employ the IDSA, ACIP, CDC, and ACP evidence-based guidelines and recommendations to:
| 1. | Prescribe vaccines according to the adult immunization schedule.
| | 2. | Use proper timing and spacing of immunobiologics.
| | 3. | Appropriately prescribe vaccines for the following vaccine preventable diseases: Influenza, Pneumococcus and Pertussis.
| | Adult Immunizations, Part II. - Upon completion of this session, using IDSA, ACIP, CDC and ACP evidence-based guidelines and recommendations, the participant should be able to:
| | 1. | Prescribe appropriate vaccines for the following vaccine preventable diseases:
| a. | Hepatitis A;
| | b. | Hepatitis B;
| | c. | Varicella-Zoster;
| | d. | Meningococcus;
| | e. | Human Papilloma Virus.
|
| | Endocarditis and Orthopedic Device Infection Prophylaxis Guidelines: What the PCP Needs to Know - Upon completion of this session, using evidence- based guidelines from the AHA, ADA, AAOS and AUA, the participant should be able to:
| | 1. | Apply current recommendations for antibiotic prophylaxis of endocarditis and prosthetic joints.
| | 2. | Illustrate data supporting prophylaxis.
| | 3. | Determine appropriate patients for prophylaxis.
| | 4. | Use proper administration of prophylactic antibiotics, including prophylaxis in the allergic patient.
| | Common Skin and Nail Infections - At the conclusion of this talk, using recommendations, statements, and guidelines from the CDC and BAD, the participant should be able to:
| | 1. | Diagnose and treat a variety of common cutaneous infections as follows:
| a. | Bacterial infections;
| | b. | Fungal infections;
| | c. | Viral infections;
| | d. | Nail infections and other nail abnormalities;
| | e. | Parasitic infestations.
|
|
| | Day 5 | Advice for the Traveler - Upon completion of this session, using recommendations from the CDC and evidence-based guidelines from IDSA, the participant should be able to::
| 1. | Recommend the general preventive measures including what not to eat and drink.
| | 2. | Order the needed immunizations.
| | 3. | Prescribe for the prevention of malaria, diarrhea and other illnesses of travelers.
| | 4. | Prescribe for the management of diarrhea of travelers.
| | HIV Primer for the Primary Care Physician - Using recommendations and evidence-based guidelines from IDSA, HIVMA, USPHS, CDC and ACP, upon completion of this session, the participant should be able to:
| | 1. | Relate the latest epidemiology of HIV infection.
| | 2. | Interpret recommendations for HIV screening.
| | 3. | Interpret diagnostic tests (e.g. viral load, CD4 count) and apply them to HIV management.
| | 4. | Illustrate the principles of antiretroviral treatment.
| | Infective Diarrhea - Using IDSA, HICPAC, CDC, FDA, and WHO evidence-based guidelines and recommendations, upon completion of this session, the participant should be able to:
| | 1. | Differentiate the presentation of toxigenic and invasive diarrhea.
| | 2. | Relate food-borne pathogens to illness.
| | 3. | Evaluate when to use fecal WBC, stool cultures, and stool O&P examinations.
| | 4. | Prescribe antibiotic therapy for various diarrheal illnesses when appropriate.
| | Community Acquired Pneumonia - Upon completion of this session, the participant should be able to use the evidence-based guidelines of the IDSA and ATS to:
| | 1. | Interpret the microbial causes of community acquired pneumonia.
| | 2. | Specify strategies utilized to triage patients to appropriate level of care.
| | 3. | Use current diagnostic tests.
| | 4. | Prescribe recommended regimens to treat community acquired pneumonia.
|
|
|